GRFS Stock Performance, Insider Transaction and News

GRFS - Grifols, S.A.

Market Cap	8.80B	P/E	28.86	EPS this Y	100.00%	Ern Qtrly Grth	-61.10%
Income	165.67M	Forward P/E	20.61	EPS next Y	48.70%	50D Avg Chg	9.00%
Sales	6.81B	PEG	0.15	EPS past 5Y	-20.77%	200D Avg Chg	21.00%
Dividend	N/A	Price/Book	2.34	EPS next 5Y	68.15%	52W High Chg	-8.00%
Recommedations	2.50	Quick Ratio	0.78	Shares Outstanding	257.44M	52W Low Chg	77.00%
Insider Own	-	ROA	2.47%	Shares Float	546.97M	Beta	0.72
Inst Own	57.75%	ROE	2.82%	Shares Shorted/Prior	5.06M/6.11M	Price	10.10
Gross Margin	38.76%	Profit Margin	2.43%	Avg. Volume	842,012	Target Price	10.69
Oper. Margin	16.19%	Earnings Date	Nov 7	Volume	1,681,821	Change	-1.56%

Healthcare | Drug Manufacturers - General | Spain

About Grifols, S.A.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Grifols, S.A. News

01:05 AM	Grifols And 2 Other Stocks That Might Be Trading Below Estimated Value
10/30/24	Grifols receives FDA approval to treat surgical bleeding with FS solution
10/29/24	Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution
10/22/24	Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
10/03/24	High Growth Tech Stocks To Watch In October 2024
10/03/24	GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
09/30/24	Brookfield reaffirms its interest in Grifols, ask more time for analysis, sources say
09/25/24	Sector Update: Health Care Stocks Fall Late Afternoon
09/13/24	Orange, Grifols Egypt Team Up to Advance Egypt's Healthcare System
08/26/24	This Reviled Pharmaceutical Firm Holds Promise of a Healthier Future
08/22/24	Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday
08/21/24	Brookfield in talks with banks for funding Grifols' takeover bid, sources say
08/21/24	European Equities Close Mostly Higher in Wednesday Trading; CMA Closes Probes Into Google, Apple
08/21/24	Grifols shares up on potential takeover by Brookfield
08/07/24	Azvalor Iberia FI's Strategic Moves in Q2 2024: Spotlight on Linea Directa Aseguradora SA
11:27 AM	Grifols: Q2 Earnings Snapshot
07:00 AM	GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339
07/29/24	Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
07/12/24	Three Stocks Estimated To Be Trading With Intrinsic Discounts Between 35.9% And 49.7%
07/09/24	Grifols Family Shareholders, Brookfield in Talks To Take Firm Private

GRFS Chatroom

briefingcom Posted - 2 days ago

$GRFS: Grifols, S.A. receives FDA approval to treat surgical bleeding in pediatric patients with its fibrin sealant solution https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241029080612GRFS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

mgus7766 Posted - 3 days ago

$GRFS https://okdiario.com/economia/brookfield-retrasa-opa-sobre-grifols-dificultad-encontrar-otros-fondos-que-acompanen-13705534

mgus7766 Posted - 1 week ago

$GRFS https://www.finanzas.com/podcasts/grifols-dara-la-campanada-con-sus-resultados.html

mgus7766 Posted - 1 week ago

$GRFS https://www.finanzas.com/ibex-35/grifols-da-argumentos-contra-la-exclusion-doblara-el-beneficio-hasta-los-132me.html

briefingcom Posted - 1 week ago

$GRFS: Grifols, S.A. partners with BARDA for proof-of-concept testing of ocular immunoglobulin as treatment for sulfur mustard-induced eye injury https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241022081452GRFS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

WeeklyTrader Posted - 2 weeks ago

Prepare for turbulence with $GRFS! RSI: 45.4% 50-day MA: $8.43 200-day MA: $7.72

mgus7766 Posted - 2 weeks ago

$GRFS

mgus7766 Posted - 2 weeks ago

Theflash88 Posted - 3 weeks ago

$GRFS SA Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage.

briefingcom Posted - 4 weeks ago

$GRFS: Grifols, S.A. subsidiary, GigaGen, has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241003080919GRFS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

MadMaverick Posted - 1 month ago

$AA $BABA $GRFS $HAS $YUMC

7xbagger Posted - 1 month ago

$GRFS Gigagen, sub of GRFS gets award up to 135million from BARDA. https://www.usaspending.gov/award/CONT_AWD_75A50124C00049_7505_-NONE-_-NONE-

MadMaverick Posted - 1 month ago

⚡ Swing Profits ⚡ $BABA +45% $AA +52% $HAS +66% $GRFS +23% $YUMC +14% #SwingTrading #stocks #investing

RI_like_AI Posted - 1 month ago

$GRFS Grifols, S.A. confirms it received CNMV notification of administrative disciplinary proceeding; considers that this sanction is not material • Grifols informs that it has received from the Spanish Securities Market Commission ("CNMV") a notification stating that its Executive Committee has decided to initiate an administrative disciplinary proceeding in connection with the report of the conclusions drawn by the CNMV dated 21 March 2024, filed by the Company as Inside Information note on the same day. In this regard, Grifols wishes to inform that the penalty proposed to be imposed on the Company for the incidents indicated in the aforementioned report of conclusions does not exceed 1,000,000. • Grifols also informs that it considers that this sanction is not material and, therefore, it will have no impact on its financial statements. Furthermore, the Company wishes to confirm that there are no new elements in the document received .